Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Finding Study of THIO Sequenced with Cemiplimab in Advanced NSCLC
2023-504595-26-00Phase 2Authorised
- Sponsor
- MAIA Biotechnology, Inc.
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of ateganosine and cemiplimab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by MAIA Biotechnology, Inc. Primary endpoints: Part A: Incidence of DLTs, Part C: Objective Response Rate (ORR, investigator-assessed) and 4 more. Planned start Jun 2024; status: authorised.
02
Drugs
ateganosinecemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504595-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504595-26-00.